Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...

Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Molecular Partners ( ...

Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...

BERKELEY, Calif., Sept. 24, 2025 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a ...

In August 2024, Bin Xia Yang, a portfolio director at the pharmaceutical company Axcynsis Therapeutics, geared up to move the company’s new tumor-fighting antibody-drug conjugate into clinical trials.

SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ --Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of ...

Positive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase ...

Serina Therapeutics is a speculative biotech with major upside after FDA feedback allows its SER-252 Parkinson’s drug to pursue the faster 505(b)(2) pathway for possible approval. The POZ technology ...